Experiment 69560
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Ginkgo biloba (GINKGOACEAE) |
| Citation | DRAGO,F: FLORIDDIA,LM: CRO,M: GIUFFRIDA,S:. (2002). PHARMACOKINETICS AND BIOAVAILABILITY OF A GINKGO BILOBA EXTRACT.. 18(2) |
| Amount utilized | |
| Compound isolated | |
| Disease | BETWEEN CYCLES.STATISTICAL ANALYSIS WAS USED TO ASSESS THE MAIN PHARMACOKINETIC PARAMETERS. THE RESULTS SHOW THAT A DOSAGE OF 40 MG TWICE DAILY (EVERY 12 HRS) IS ACCOMPANIED BY A SIGNIFICANTLY LONGER HALF-LIFE (T 1/2) AND MEAN RESIDENCE TIME BILOBA EXTRACT,80 MG ONCE DAILY AND 40 MG TWICE DAILY FOR 7 DAYS. 12 HEALTHY VOLUNTEERS TOOK PART IN THE STUDY. THEY WERE RANDOMLY ASSIGNED TO ONE OF THE TWO TREATMENT GROUPS: 40 MG TWICE DAILY OR 80 MG ONCE DAILY, WITH AN INTERVAL OF 21 DAYS THE AIM OF THE PRESENT STUDY WAS TO ASSESS THE BIOAVAILABILITY OF THE MAIN ACTIVE INGREDIENT IN GINKGO BILOBA EXTRACT, GINKGOLIDE B.THE STUDY ALSO FOCUSED ON THE PHARMACOKINETICS OF TWO DIFFERENT DOSAGE REGIMENS FOR ORALLY ADMINISTERED GINKGO (MRT) THAN A SINGLE 80 MG DOSE, EVEN THOUGH THE LATTER CAUSES A HIGHER CONCENTRATION PEAK (C-MAX). THE MAXIMUM CONCENTRATION TIME (T-MAX) IS 2.3 HRS AFTER ADMINSTRATION IN BOTH TREATMENTS. A COMMERCIAL PRODUCT, EGB-761, WAS USED. |
| Dose amount | 80.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | TYPE EXT NOT STATED |
| Gender | MALE |